Skin Diseases, Infectious Clinical Trial
Official title:
Effect of an Antiseptic Solution on the Skin Microbiome
NCT number | NCT05608382 |
Other study ID # | SGW2022 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 7, 2022 |
Est. completion date | March 18, 2022 |
Verified date | October 2022 |
Source | Center for Innovation and Research Organization |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is simulate the clinical use of an antiseptic solution in a 24 hour window and the recovery to baseline conditions at 1 month following application. Efficacy will be simulated as the capacity of the material to reduce or clear the skin bacterial population from a representative skin area: the anteromedial forearm.
Status | Completed |
Enrollment | 50 |
Est. completion date | March 18, 2022 |
Est. primary completion date | March 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: A subject may be eligible for study participation if all of the following criteria are met: 1. Subject is male or female greater than 18 years of age. 2. Subject does not have a history of skin allergies/atopia (e.g. atopic dermatitis). 3. Subject does not have a history of skin disease (e.g scleroderma, vitiligo, psoriasis) or a chronic systemic disease affecting the skin (e.g systemic lupus erythematosus). 4. Subject is willing to have materials applied and follow the protocol. 5. Subject agrees to avoid exposure of the test sites to the sun, chemical product, clothes and to refrain from touching the area of application (for T0 [baseline], T1 [5 minutes], T2 [2 hours]). 6. Subject agrees to refrain from getting a bath/shower before T3 (24 h). 7. Subject agrees to avoid scrubbing, applying, and/or washing the test area with new soap, moistures, powders, lotions, cosmetic or toiletry products during the study. 8. Subject is able to follow directions as outlined in the protocol and anticipates being available for all study visits. 9. Subject is willing to participate in all study evaluations. 10. Subject is in generally good health. 11. Subject is willing to sign the Informed Consent form prior to study participation Exclusion Criteria: 1. Female subject is pregnant, nursing, planning a pregnancy, or not using adequate birth control. 2. Subject is immunologically compromised or has received specific topical treatment (antimicrobial or not-antimicrobial), during the last month. 3. Subject reports a history of allergies to antiseptics. 4. Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study. 5. Subject has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs. |
Country | Name | City | State |
---|---|---|---|
United States | Center for Innovation and Research Organization | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Center for Innovation and Research Organization |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Colony Forming Unit (CFU) count | Comparison of the number of CFUs counted for each treatment arm | 5 minutes | |
Primary | Colony Forming Unit (CFU) count | Comparison of the number of CFUs counted for each treatment arm | 2 hours | |
Primary | Colony Forming Unit (CFU) count | Comparison of the number of CFUs counted for each treatment arm | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00746109 -
Study of Wound Packing After Superficial Skin Abscess Drainage
|
Phase 4 | |
Completed |
NCT00210899 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT00761215 -
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT00228982 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT01967225 -
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
|
Phase 3 | |
Withdrawn |
NCT00990392 -
Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections
|
N/A | |
Completed |
NCT00228410 -
Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
Completed |
NCT02276482 -
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
|
Phase 3 | |
Completed |
NCT00198679 -
Effect of Chlorhexidine Skin Cleansing on Skin Flora
|
Phase 4 | |
Completed |
NCT03981822 -
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
|
Phase 2 | |
Completed |
NCT00711802 -
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
|
Phase 4 | |
Completed |
NCT00488761 -
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI
|
Phase 4 | |
Completed |
NCT00679302 -
Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
|
Phase 4 | |
Completed |
NCT00257036 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin
|
Phase 2/Phase 3 | |
Completed |
NCT04485676 -
Dalbavancin in Real Clinical Practice in Spain
|
||
Completed |
NCT00785200 -
MRSA Colonization and Control in the Dallas County Jail
|
N/A | |
Completed |
NCT00257062 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin
|
Phase 3 | |
Completed |
NCT02582203 -
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
|
Phase 4 | |
Completed |
NCT00388310 -
Effective Antibiotic Treatment of MRSA
|
N/A |